Dr. Laura Miller - Comparative analysis of signature genes in PRRSV-infected porcine monocyte-derived dendritic cells at differential activation statuses
Comparative analysis of signature genes in PRRSV-infected porcine monocyte-derived dendritic cells at differential activation statuses - Dr. Laura Miller, Virus and Prion Diseases of Livestock Research Unit, National Animal Disease Center, USDA-ARS, from the 2015 North American PRRS Symposium, December 4 - 5, 2015, Chicago, IL, USA.
More presentations at http://www.swinecast.com/2015-north-american-prrs-symposium
Reduced Antimony Accumulation in ARM58-Overexpressing Leishmania infantum
Semelhante a Dr. Laura Miller - Comparative analysis of signature genes in PRRSV-infected porcine monocyte-derived dendritic cells at differential activation statuses
Semelhante a Dr. Laura Miller - Comparative analysis of signature genes in PRRSV-infected porcine monocyte-derived dendritic cells at differential activation statuses (20)
300003-World Science Day For Peace And Development.pptx
Dr. Laura Miller - Comparative analysis of signature genes in PRRSV-infected porcine monocyte-derived dendritic cells at differential activation statuses
1. Comparative analysis of signature genes in PRRSV-
infected porcine monocyte-derived dendritic cells at
differential activation statuses.
Laura Miller, USDA-ARS (Co-PD)
Yongming Sang, KSU (PD)
Raymond R. R. Rowland, KSU (Co-PD)
Frank Blecha, KSU (Co-PD)
College of Veterinary Medicine
Kansas State University, Manhattan, KS 66506, USA
2. Activation statuses of monocytic cells including monocytes, macrophages and
dendritic cells (DCs) are critically important for antiviral immunity. In
particular, some devastating viruses, including porcine reproductive and
respiratory syndrome virus (PRRSV), are capable of directly infecting these
cells to subvert host immunity.
Introduction
3. Table 1. Monocytotropic viruses and pathogenic effect of macrophage manipulation/infection
Virus*
[genome, family]
Macrophage-related primary infection cells/sites Effect of manipulation/infection in monocytes, MΦs and DCs
DENV
[(+)ssRNA, Flaviviridae]
Monocytes, MΦs and DCs in multiple tissues of IFN-αβγR
KO mice
MΦ-depletion: Tenfold increase in systemic viral titer, and massive infiltration of
monocytes
RSV
[(-)ssRNA, Paramyxoviridae]
Blood monocytes, DCs, lung epithelial cells and MΦs in
mice/humans
MΦ-depletion: Abolished local inflammatory cytokine peak at 1 dpi, and enhanced viral
load in the lung at 4 dpi
HIV1
[(+)ssRNA, Retroviridae]
Macrophages and T cells in humans Deficiency of CCR5, a co-receptor that mediates HIV macrophage-tropism, showed
resistance to HIV-1infection
WNV
[(+)ssRNA, Flaviviridae]
Murine keratinocytes and skin-resident DCs, and probable
peripheral MΦs and DCs mediating neuroinvasion
MΦ-depletion: Higher and extended viremia, and accelerated encephalitis and death.
Inhibition of NOS activity of infiltrating MΦs relieved encephalitis and prolonged survival
SARS-Cov
[(+)ssRNA, Coronaviridae]
Human respiratory epithelial cells, and antibody-enhanced
infection of macrophages and immune cells
Depletion of alveolar MΦs 1-2 day before infection, (but not at 2 dpi), prevented lethal
disease, and enhanced viral clearance
IAV
[Segmented (-)RNA, Orthomyxoviridae]
Airway and lung epithelial cells, DCs, and MΦs of
mice/humans/pigs
MΦ-depletion: Strain-dependent exacerbation of viral replication, increased airway
inflammation and viral pneumonia
CSFV
[(+)ssRNA, Flaviviridae]
Porcine blood monocytes/macrophages Viral infection stimulated arginase-1 (ARG-1) but suppressed nitric oxide synthase (iNOS)
expression, i.e., induced M1-M2 repolarization
PrV
[dsRNA, Herpesviridae]
Porcine lung epithelial cells and MΦs and spread via
infected blood monocytes
Acute IFN-α response is important in diminishing the spread of PrV in the connective tissue
but not in epithelial cells (IFN cell preferences)
ASFV
[dsRNA, Asfarviridae]
Primarily and persistently infected tissue
monocytes/ MΦs and fibroblasts in multiple tissues
Massive M1 polarization served as a modulator of the viral pathogenesis including
pulmonary edema, hemorrhage, and lymphoid depletion that characterize the disease
PCV2
[ssDNA, Circoviridae]
Monocyte/MΦ lineage cells, including alveolar MΦs, are the
major target cells
Acute infection reduced alveolar MΦs phagocytosis and microbicidal capability; and
persistence increased inflammatory and pro-apoptotic responses, which led to
lymphopenia and immunosuppression
FMDV
[(+)ssRNA, Picornaviridae]
Early infection of porcine T and B cells caused viremia;
immunocomplex promoted productive infection and killing
of mDCs
Increase IL-10 production in infected DCs, loss of pDC cell function coincides with
lymphopenia in FMDV-infected pigs; macrophage depletion in vaccinated mice severely
decreased vaccine protection
PRRSV
[(+)ssRNA, Arteriviridae]
Tissue macrophages, monocytes and mDCs especially those
in reproductive and respiratory tracts.
Massive cell death of infected monocytic cells; increase of IL-10 and reduction of
phagocytic, microbicidal, pro-inflammatory, and antigen-presentation activity in MΦs and
DCs. Pathogenicity-related suppression of IFN-α production in pDCs.
Sang Y, Miller LC, Blecha F. Macrophage Polarization in Virus-Host Interactions. J Clin Cell Immunol. 2015 Apr;6(2). pii: 311.
4. Objectives
Our long-term goal is two-fold:
1) to integrate activation status with antiviral responses in monocytic cells
2) to functionally modulate them for a prototypic cellular adjuvant/vaccine that is ideal for
potentiating antiviral immunity.
5. Methods
• To study how PRRSV infection alters cell activation, we have systematically
characterized the activation status and determined, genome-wide, signature genes
regulating the activation status in porcine monocytic innate immune cells with PRRSV
pathogenicity in ex-vivo stimulated cells using our established RNA-seq procedure.
• Porcine monocyte-derived dendritic cells (mDCs) were polarized with mediators (PBS,
IFN-γ, IL-4, LPS, IL-10, IFN-α) for 30 hours, then mock-infected, or infected with PRRSV
strain VR-2332, or highly pathogenic PRRSV strain HP-PRRSV rJXwn06, for 5 h.
• Each sample represents a pooled RNA from four replicates.
6. Methods
Comparisons were made within each treatment group of activation status (mediator vs.
PBS control) and between treatment group for each mediator.
CTRL Grp I:
Polarization
mediators
PRRSV
(moi: 0.1)
1 PBS -
2 IFNγ -
3 IL4 -
4 LPS -
5 IL10 -
6 IFNα -
VR Grp II:
Polarization
mediators
PRRSV
(moi: 0.1)
1V PBS VR2332
2V IFNγ VR2332
3V IL4 VR2332
4V LPS VR2332
5V IL10 VR2332
6V IFNα VR2332
HP Grp III:
Polarization
mediators
PRRSV
(moi: 0.1)
1H PBS HP-JX
2H IFNγ HP-JX
3H IL4 HP-JX
4H LPS HP-JX
5H IL10 HP-JX
6H IFNα HP-JX
Table 1. Sample organization table
12. Polarization mediators Control vs PBS VR2332 vs PBS HP-PRRSV vs PBS
IFN-γ
RNA ALDH POSTN
ACT ACAN ACT
RNA TNN COL
CXCL COL CXCL
SAA CXCL SAA
UBD POSTN UBD
IDO1 COL SAA
IL-4
COL THBS1 RNA
COL CYTB RNA
ACT MMP RNaseP
CXCL POSTN CXCL
IL-17 SFRP2 CDH2
CDH2 CXCL IL17RB
LPS
COL TNN RNaseP
ACT COL U splicesomal RNA
RNA GJA1 RNA
SAA IL1B SAA
IDO1 SAA MMP
IL1B CXCL IL1B
IL-10
RNA DEFB133 RNA
IFIT1 IL2RA RNaseP
RNA S100A1 U splicesomal RNA
MMP CELSR1 MMP
SAA GTSE1 IL7
IL7 TTC38 MMP
IFN-α
RNA THBS1 RNA
ACT CYTB RNaseP
RNaseP IL1B U splicesomal RNA
ISG12 ISG12 ISG12
TNF IRG6 XAF1
IFI IFIT1/IFIT2 IFIT1
CTRL Grp I:
Polarization
mediators
PRRSV
(moiI: 0.1)
1 PBS -
2 IFNg -
3 IL4 -
4 LPS -
5 IL10 -
6 IFNa -
VR Grp II:
1V PBS VR2332
2V IFNg VR2332
3V IL4 VR2332
4V LPS VR2332
5V IL10 VR2332
6V IFNa VR2332
HP Grp III:
1H PBS HP-JX
2H IFNg HP-JX
3H IL4 HP-JX
4H LPS HP-JX
5H IL10 HP-JX
6H IFNa HP-JX
2 vs 1
3 vs 1
4 vs 1
5 vs 1
6 vs 1
2V vs 1V
3V vs 1V
4V vs 1V
5V vs 1V
6V vs 1V
2H vs 1H
3H vs 1H
4H vs 1H
5H vs 1H
6H vs 1H
Results and discussion
13. DE Polarization mediators VR-2332 HP-PRRS
é
PBS
RNA CXCL10
RNaseP RNA
ACT ISG12
ê
MORC3 AREG
TNN U splicesomal RNA
TNFSF10 CXCL2
é
IFN-γ
ETNPPL IRG6
CYP1A1 COL
COL FAM111C
ê
POSTN RNA
CCL11 U splicesomal RNA
CAV2 RNaseP
é
IL-4
RNA RNA
RNaseP RNaseP
U spliceosomal RNA U splicesomal RNA
ê
POSTN POSTN
IRG6 COL
IFIT1/IFIT2 SFRP2
é
LPS
LAG3 CXCL10
MARCO IRG6
TRBV19 IFIT1/IFIT2/IFIT3
ê
TGM2 COL1A2
MMP COL3A1
IL1A POSTN
é
IL-10
ACT RNA
COL RNaseP
COL RNA
ê
UBCH5B CCNL1
IL1A SEPINB2
CXCL2 CXCL2
é
IFN-α
COL1A2 CXCL10
COL1A2 IRG6
COL6A3 IFIT3/IFIT5/IFIT2
ê
PMAIP1 WNT5A
RNA AREG
CXCL10 MMP
1V vs 1
2V vs 2
3V vs 3
4V vs 4
5V vs 5
6V vs 6
1H vs 1
2H vs 2
3H vs 3
4H vs 4
5H vs 5
6H vs 6
DE Polarization mediators VR2332 vs HP-PRRS
PBS
CXCL10
IRG6
IFIT1
COL3A1
RNA
COL1A2
IFN-γ
POSTN
MXRA5
IRG6
RNA
RNaseP
U splicesomal RNA
IL-4
CXCL10
IRG6
IFIT1/IFIT2/IFIT3
ACTA2
CAV1
COL3A1/CXCL2
LPS
IRG6
CXCL10
IFIT1/IFIT2/IFIT3
COL1A2
COL3A1
SFRP2
IL-10
CXCL10
IRG6
IFIT1
COL3A1
ACTA2
COL1A2
IFN-α
CXCL10
IRG6
IFIT3
COL1A2
COL3A1
COL5A2
1H vs 1V
2H vs 2V
3H vs 3V
4H vs 4V
5H vs 5V
6H vs 6V
Results and discussion
14. • Clustering of samples was consistent with virus strain and then by mediator.
• Many of the genes showing the most variability were related to cellular structure and
innate immune response.
• The magnitude of differentially expressed gene profiles detected in HP-PRRSV rJXwn06
infected mDCs as compared to VR-2332 infected mDCs was consistent with the
increased pathogenicity of the HP-PRRSV in vivo.
Conclusions
15. Experiment I.
Group N Treatment Dpi 7
Blood
PBMCs,
BALF
Dpi 14
Blood
PBMCs,
BALF
1 6 Control – sham # #
2 6 Ing. MLV # #
3 6 VR-2332 # #
Experiment II.
Group N Treatment Dpi 7
Blood
PBMCs,
BALF
Dpi 14
Blood
PBMCs,
BALF
1 6 Control – sham # #
2 10 rJXwn06 # #
Cytokine and signature gene phenotyping to correlate cell activation statuses with PRRSV pathogenicity.
Blood –Whole-blood and PBMCs for isolation of monocytes, cDC and pDCs
Broncheo-alveolar lug fluid (BALF)
Correlate cell activation status with PRRSV pathogenicity in primary cells isolated from virus-infected pigs.
Current/future work
Real-time RT-PCR
Comparisons:
1) treatments of control, vaccinated and infected;
2) pigs within a treatment;
3) groups of the monocytic cells; and
4) subsets of MФs and DCs.
Flow (FSC)
PBMC
Panel #1 CD4+ CD8+ CD172a+
Panel #2 CD80+ MHCIIHi MHCIIlo
Panel #3 CD16+ CD163+ MHCIIHi MHCIIlo
Panel #4 CD163+ SDOW17+
BALF
Panel #2 CD80+ MHCIIHi MHCIIlo
Panel #3 CD16+ CD163+ MHCIIHi MHCIIlo
16. Correlate cell activation status with PRRSV pathogenicity in primary cells isolated from virus-infected pigs.
Current/future work
17. Acknowledgements
Technicians: Sarah Anderson USDA ARS NADC
Sequencing: ISU DNA facility
Bioinformatics: Dr Darrell Bayles, USDA ARS NADC
Animal study: Dr Vikas Kulshrestha, Dr Albert Van Geelen, Dr Alexa Buckley, Dr Nestor
Montiel, Dr Kelly Lager, Sarah Anderson, NADC animal caretakers
Flow cytometry: Sam Humphrey USDA ARS NADC
Flow cytometry analyses: Dr Nestor Montiel, Sam Humphrey USDA ARS NADC
Funding: This work was supported by USDA NIFA AFRI grant 2013-67015-21236
18. CTRL
Fluorescent
ToFA
(2.5 μg/ml)
ToFA
(5 μg/ml)
mDCs infected with DsRed-PRRSV for 48 h
Merged
ToFA (5-(Tetradecyloxy)-2-furoic acid), a competitive
inhibitor of acetyl-CoA carboxylase (ACC)
FL1 (PRRSV)
99.42 0.58
100 101 102 103 104
MФsMARC-145 mDCs
6.09 93.91
83.16 16.84
98.52 1.48
43.26 56.74
62.55 37.45
74.51 25.49
86.97 13.02
98.96 1.04
100 101 102 103 104 100 101 102 103 104
FSC-H
1000
800
600
400
200
0
1000
800
600
400
200
0
1000
800
600
400
200
0
MockPRRSVToFA+PRRSV
Sang et al. Animal Health Review 2011, 12:149-67. PLoS One. 2014, 9:e87613. and J. Virol. 2014, Oct;88(19):11395-410.
Antiviral regulation via AMPK pathway and lipid metabolism
Develop a prototypic adjuvant/vaccine system based on functional modulation of activation statuses in
porcine monocytic innate immune cells
19. ORF1a
ORF1b
ORF2-7
AflII
MluI
IFN ORF6X Histidine tag
12-AA protease cleavage site
Vector CMV promoter
Viral RNA cDNA
Sang et al., Viruses. 2012, 4:102-16; J. Virol. 2014, Oct;88(19):11395-410.
Anti-PRRSV N
Anti-IFNα Merged
Virus-replication competent IFN expression: acts against viral
suppression of IFN production in situ
Validation for Therapeutic Designs
20. Sang et al. Animal Health Review 2011, 12:149-67, and J. Virol. 2014, 88(19):11395-410. Brockmeier et al., Clin Vaccine Immunol. 2012, 19:508-14.
3. Synthetic/natural
lipids
2. Metabolic
mediators,
such as
ToFA
1. Virus-replication competent
IFN expression
Regulatory
lipid nano-particle
(LNP)
Validation for Therapeutic Designs
21. Cytokine and signature gene phenotyping to correlate cell activation
statuses with PRRSV pathogenicity.
Blood –Whole-blood and PBMCs for isolation of monocytes, cDC
and pDCs (LM)
BALF –LM
Samples prepped for flow cytometry/sorting
RT-PCR (RNAlater) and Searchlight (cytokine buffer.
22. The 2015 North American PRRS Symposium wishes to thank
the following sponsors for their generous support:
Notas do Editor
It is in the first year of this 4-yr project, in which we intend to study the antiviral regulation and virus-cell interaction in porcine monocytic cells.
Activation statuses of monocytic cells including monocytes, macrophages (MΦs) and dendritic cells (DCs) are critically important for antiviral immunity. Unfortunately, the activation status of porcine monocytic cells or how cell activation status functionally interacts with antiviral immunity remains largely unknown. This is a significant omission because many economically important porcine viruses are monocytotropic including our focus, porcine reproductive and respiratory syndrome virus (PRRSV). Understanding the relationships of activation status and antiviral states not only extends the activation paradigm of these cells but also integrates innate immune responses with several aspects of inflammation, tissue repair and overall antimicrobial activity. This is important because most PRRSV infections are syndromes complicated with co-infection from pathogens of other phyla. Therefore, integration of conventional activation status and antiviral states provides a framework for potentiation of overall immune response to PRRS disease. PRRSV is ideal for deciphering how monocytic cell activation statuses interact with antiviral immunity, because it directly infects subsets of MΦs and DCs and subverts overall immune responses.
Activation statuses of monocytic cells including monocytes, macrophages and dendritic cells (DCs) are critically important for antiviral immunity. In particular, some devastating viruses, including porcine reproductive and respiratory syndrome virus (PRRSV), are capable of directly infecting these cells to subvert host immunity.
The overall similarity between samples was assessed in heat map plots calculating both the Euclidean distance (Fig. 1A) and Poisson distance (Fig. 1B) between regularized log transformed data to allow equal contribution from all genes. Principal component analysis (PCA) estimates were used to emphasize variations in comparisons (Fig. 1C&D). Poisson distance using the original counts and the technique of multidimensional scaling was used to simplify the clustering.
Principal component analysis (PCA) estimates were used to emphasize variations in comparisons (Fig. 1C&D). Poisson distance using the original counts and the technique of multidimensional scaling was used to simplify the clustering.
Whether a gene effect is called significant depends not only on its log fold change in expression, but also on its within-group variability, which DESeq2 quantifies as the dispersion. For strongly expressed genes, the dispersion can be understood as a squared coefficient of variation: a dispersion value of 0.01 means that the gene's expression tends to differ by typically √0.01 =10% between samples of the same treatment group. For weak genes, the Poisson noise is an additional source of noise.
The black points are the dispersion estimates for each gene as obtained by considering the information from each gene separately. Unless one has many samples, these values fluctuate strongly around their true values. Therefore, we fit the red trend line, which shows the dispersions' dependence on the mean, and then shrink each gene's estimate towards the red line to obtain the final estimates (blue points) that are then used in the hypothesis test. The blue circles above the main "cloud" of points are genes which have high gene-wise dispersion estimates which are labeled as dispersion outliers. These estimates are therefore not shrunk toward the fitted trend line.
In these plots, we have not tried to do any comparison of differential expression; rather, we simple look at each gene across all treatments and ask which 35 genes show the most variability. We then create a heat map using those 35 genes. The logic is that the most variable genes are most likely to be the genes that will provide the most resolution for clustering the samples. The bar along the top of the plot highlights the location of the three virus types.
The black points are the dispersion estimates for each gene as obtained by considering the information from each gene separately. Unless one has many samples, these values fluctuate strongly around their true values. Therefore, we fit the red trend line, which shows the dispersions' dependence on the mean, and then shrink each gene's estimate towards the red line to obtain the final estimates (blue points) that are then used in the hypothesis test. The blue circles above the main "cloud" of points are genes which have high gene-wise dispersion estimates which are labeled as dispersion outliers. These estimates are therefore not shrunk toward the fitted trend line.
In these plots, we have not tried to do any comparison of differential expression; rather, we simple look at each gene across all treatments and ask which 35 genes show the most variability. We then create a heat map using those 35 genes. The logic is that the most variable genes are most likely to be the genes that will provide the most resolution for clustering the samples. The bar along the top of the plot highlights the location of the three virus types.
The black points are the dispersion estimates for each gene as obtained by considering the information from each gene separately. Unless one has many samples, these values fluctuate strongly around their true values. Therefore, we fit the red trend line, which shows the dispersions' dependence on the mean, and then shrink each gene's estimate towards the red line to obtain the final estimates (blue points) that are then used in the hypothesis test. The blue circles above the main "cloud" of points are genes which have high gene-wise dispersion estimates which are labeled as dispersion outliers. These estimates are therefore not shrunk toward the fitted trend line.
Cell treatment: Porcine mDCs, polarized with mediators for 30 h, then mock-infected (control: 1-6), infected with VR2332 (1V-6V) or infected with HP-PRRSV (1H-6H, JX strain from Jishu) for 5 h. Each sample represents a pooled samples from four replicates.
Comparison: Compare each activation status (2-6) to the PBS treatment within each control and infected groups
Compare between infected with uninfected, and infected (V) with infected (HP), i.e.:
We adopt a lipid nanoparticle to combine the antiviral regulatory role of some metabolic mediator and vaccine backbone. For example, we have developed procedure to incorporate ToFA, the lipid metabolism regulator, into a lipid nanoparticle, then the lipid nanoparticle will be used to encapsulate bioengineered vaccine backbone, as I showed you previously, we have validate the antiviral effect of most of these vaccine component in cells. My collaborator, Dr. Laura Miller in USDA, has validated anti-PRRSV effect of the virus expressed IFN, they showed that only timely an effective IFN alone could stimulate effective anti-PRRSV activity. We believe, the system of IFN-expressed PRRSV system, will provide better immune potentiation through introducing both IFN and viral antigens to mimic wide-type PRRSV infection timely and in situ. With this, I will deliver some messages of my research primarily presented so far. (Read out)
In the third part, I will brief our validation of potential antiviral approaches in both cells and animals. To potentiate antiviral activity through modulation of lipid metabolism, we have tested dozens of agonists or antagonists in lipid metabolism, one competitive inhibitorof acetyl-CoA carboxylase (ACC) , ToFA, was among several effective drugs to potentiate anti-PRRSV activity in our cell models. At the dose without causing visible cell toxicity, ToFA could suppress nearing 90% PRRSV infection in MARC-145 cell line, and nearing 50% in both porcine macrophages and dendritic cells. And these are the images to show ToFA’s dose dependence in dendritic cells, again ToFA at 5 ug/ml significantly suppressed PRRSV infection.
As you know, suppression of IFN production is a major mechanism for many viruses to establish infection in animals. To reverse PRRSV’s effect on IFN suppression, we bioengineered PRRSV to express IFN. To achieve this, we manipulated a cDNA infectious clone of a PRRSV, and it is not problem to fuse a IFN gene into the PRRSV’s expression cassette. The problem is to coordinate the IFN expression with virus replication, ie. PRRSV replication-competent IFN expression, because IFN expression is inhibitive to PRRSV replication, but without sufficient PRRSV replication, we can not produce enough IFN, in addition for vaccine design, it is required for virus to replicate to some extent to induce antiviral immunity. To solve this problem, we introduced a leader sequence in front of the IFN coding regions, this leader includes a cleavage site for a macrophage-specific protease (cathepsin), therefore, we can produce enough engineered virus in the MARC-145 cells. As you see, IFN peptide was successfully expressed and cleaved from the leader sequence by a protease treatment, and the overexpression of leader-linked IFN was co-localized in MARC-cells. Significantly, when we infected porcine macrophages with the bioengineered virus and co-infected GFP-labeled PRRSV virus, the IFN-expression virus with expression of full-length of IFNa6 dramatically suppress co-infected PRRSV virus, and this suppression is dependent on the release of IFN peptides by the macrophage protease, and appropriate compartmentalization is also critical for expressed IFN to exert antiviral function, as shown that the virus expressing the leader-linked mature IFN have little effect to suppress PRRSV infection. Not only suppress co-infected PRRSV infection, the transfection of IFNA6-expressed virus also prevent the cells from PRRSV induced cell lysis for 96 h post PRRSV infection.
We adopt a lipid nanoparticle to combine the antiviral regulatory role of some metabolic mediator and vaccine backbone. For example, we have developed procedure to incorporate ToFA, the lipid metabolism regulator, into a lipid nanoparticle, then the lipid nanoparticle will be used to encapsulate bioengineered vaccine backbone, as I showed you previously, we have validate the antiviral effect of most of these vaccine component in cells. My collaborator, Dr. Laura Miller in USDA, has validated anti-PRRSV effect of the virus expressed IFN, they showed that only timely an effective IFN alone could stimulate effective anti-PRRSV activity. We believe, the system of IFN-expressed PRRSV system, will provide better immune potentiation through introducing both IFN and viral antigens to mimic wide-type PRRSV infection timely and in situ. With this, I will deliver some messages of my research primarily presented so far. (Read out)
Montanide Gel01 ST adjuvant enhances MLV efficacy
ToFA (inhibitor of acetyl Co-A carboxylase, enzyme in lipid metabolism suppresses PRRSV infection